Eli Lilly, Pharmaceutical
Digest more
GSK invests £22bn in US to coincide with Trump's state visit
Digest more
Bright Green Corporation merges with PharmAGRI Capital Partners, will restore US drug manufacturing sovereignty with $10B deal for Tesla's humanoid robots.
Merck and AstraZeneca say the United Kingdom is not spending enough on medicines, but experts say it’s a symptom of underlying weaknesses in the global pharmaceutical sector.
GSK, the British pharmaceutical company, is the latest to join the club. The company has pledged to invest $30 billion in establishing manufacturing, research, and supply chain facilities in the US over the next 5 years. The announcement came on Sept. 17, during Trump’s recent 3-day visit to the UK.
CORK is set for a major employment boost as a pharmaceutical manufacturing facility is set to bring 200 new jobs. Merck have officially opened the doors to their €150million euro site at Blarney
Despite regulatory uncertainties and tariffs casting a shadow on pharma exports to the US United States, its largest export market, the Indian pharmaceutical industry expects to see “moderate growth” of between 7 and 9 per cent in the current financial year (FY 26),
Since coming into power last year, Rachel Reeves and Keir Starmer have consistently stressed the importance of the life science sector to the UK economy, viewing it as critical for growth. In its aim to boost the industry’s standing,
Rising costs, policy barriers, and shrinking incentives are driving Big Pharma away from the UK, as major companies pause r&d projects
Feedback